Compare Neurocrine Biosciences Inc (NBIX) vs Stanley Black & Decker, Inc. (SWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Stanley Black & Decker, Inc. — how do they compare? Neurocrine Biosciences Inc trades at $155.5 (market cap $15.77B), while Stanley Black & Decker, Inc. trades at $91.6 (market cap $14.17B). The key difference: Neurocrine Biosciences Inc and Stanley Black & Decker, Inc. are close in size by market cap, and Stanley Black & Decker, Inc. pays a 3.58% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | SWK | |
|---|---|---|
Market Cap | $15.77B | $14.17B |
Sector | Health | — |
52-Week High | $185.50 | $104.00 |
52-Week Low | $123.10 | $62.12 |
Enterprise Value | $15.78B | $18.33B |
Dividend Yield | — | 3.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Stanley Black & Decker (SWK) trades at $93.81, down 3.65% on the day, with a bearish technical signal from moving averages and oscillators. The company reported three consecutive quarterly earnings beats, with Q3 2026 results pending. Recent portfolio refinement includes the sale of Excel Industries to Bad Boy Mowers. Valuation metrics show a P/E of 22.94 and P/S of 0.93, with a net income margin of 4.07% for 2025.
The outlook is mixed: analyst consensus is a $98.50 price target with 43% buy ratings, but technical indicators suggest near-term pressure. Opportunities include cost transformation benefits and dividend stability, while risks involve debt levels and industrial demand volatility. The stock's current price is near the low end of analyst targets, indicating potential upside if fundamentals strengthen.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →
